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Methamphetamine is a potent psychostimulant that can induce psychosis among
recreational and chronic users, with some users developing a persistent psychotic
syndrome that shows similarities to schizophrenia. This review provides a comprehensive
critique of research that has directly compared schizophrenia with acute and
chronic METH psychosis, with particular focus on psychiatric and neurocognitive
symptomatology. We conclude that while there is considerable overlap in the behavioral
and cognitive symptoms between METH psychosis and schizophrenia, there appears
to be some evidence that suggests there are divergent aspects to each condition,
particularly with acute METH psychosis. Schizophrenia appears to be associated with
pronounced thought disorder, negative symptoms more generally and cognitive deficits
mediated by the parietal cortex, such as difficulties with selective visual attention, while
visual and tactile hallucinations appear to be more prevalent in acute METH-induced
psychosis. As such, acute METH psychosis may represent a distinct psychotic disorder
to schizophrenia and could be clinically distinguished from a primary psychotic disorder
based on the aforementioned behavioral and cognitive sequelae. Preliminary evidence,
on the other hand, suggests that chronic METH psychosis may be clinically similar to
that of primary psychotic disorders, particularly with respect to positive and cognitive
symptomatology, although negative symptoms appear to be more pronounced in
schizophrenia. Limitations of the literature and avenues for future research are also
discussed.
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METHAMPHETAMINE
Amphetamines refer to a class of chemically related compounds that have been used extensively
over the last century in both recreational and medicinal settings, with various amphetamine
analogs used in the treatment of narcolepsy, attention deficit hyperactivity disorder (ADHD) and
obesity (1, 2). Methamphetamine (METH; N-methyl-alpha-methylphenethylamine) is a highly
potent amphetamine derivative that is frequently abused worldwide and has significant effects
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on physical, behavioral, cognitive and psychiatric output (3).
It is a cationic molecule and chiral compound based around
a phenylethylamine core (4), and distinguishable from its
amphetamine analogs by an additional methyl group. This
methyl addition reportedly makes METH highly lipophilic,
thereby allowing it to increasingly penetrate the blood-brain
barrier (5). This causes changes to dopaminergic, serotonergic,
and noradrenergic systems via the stimulated release of
monoamines, the inhibition and reversal of monoamine
reuptake, inactivation of presynaptic vesicular monoamine
transporter 2, and by reducing the efficacy of monoamine
metabolic enzymes (6–10). Although all three monoamine
systems are involved, the behavioral and reinforcing properties
of METH have typically been associated with dopaminergic
neurotransmission, particularly in the mesocorticolimbic
pathway (11, 12).
Epidemiological studies place amphetamine-type stimulants
as the most widely used illicit drug in the world after cannabis
(13, 14), with up to 51 million users globally between 15 and 64
years old (15–17). Worldwide statistics on METH use describe
it as a global phenomenon, with METH consumption reportedly
independent of wealth, geographical location, and culture (18).
Recent reports suggest an increased production ofMETH around
the world and an increasing popularity of METH over the last
5–15 years, which has been linked to increased ease and cost-
effective synthesis in clandestine laboratories and augmented
importation of METH from Mexico and Asia (16, 19). Indeed,
worldwide seizures relating to METH have been greater than any
other drug category (17). Additionally, admissions to treatment
programs for METH use increased 255% from 1997 to 2007 in
the USA (20, 21), although there is some evidence that the rate
of admissions for METH in the USA have remained stable or
slightly declined from 2004 to 2014 (22). In Australia, there has
been a 233% increase in demand for METH related treatment
and a 274% increase in METH related hospital admissions since
2010 (23, 24), with Queensland specifically witnessing a 20-fold
increase in METH related hospital admissions from 2009 to
2015 (25).
METH is available in various forms and at different levels
of chemical purity. When injected, snorted, or inhaled, METH
has direct access to the circulatory system and therefore has
more immediate effects on the brain (26, 27). Given that the
negative consequences of METH are associated with the use
of more potent forms of the drug and with hazardous routes
of administration (i.e., injection), the increased availability of
crystalline METH on the illegal market had resulted in a
significant increase in METH’s popularity amongst dependent
and intravenous drug-taking populations (28). Indeed, while 22%
of METH users reported that crystallized METH was their drug
of choice in 2010 (29), this had increased to 50% by 2013 (30).
These trends are salient given the potential for addiction and
overdose with more potent forms of METH administration.
ACUTE METHAMPHETAMINE PSYCHOSIS
Dependency to METH, together with high doses and
recreational METH use, have all been associated with the
induction of psychotic symptoms, including auditory and
visual hallucinations, persecutory delusions, ideas of reference,
and disorganized speech (31–33). The idea that METH use
could induce a psychotic state has long been recognized by
clinicians in Japan, who increasingly observed psychosis in their
METH-dependent patients (34). The early identification of this
relationship was due, in part, to the high prevalence of METH
use together with the absence of polydrug use, thereby enabling
clinicians to isolate the link between METH and psychosis
without the confound of additional substance use (35).
Research has shown that METH psychosis is a prevalent
health concern among recreational users. Studies on prevalence
rates have varied between 7% (32) up to 76% (36), with a
recent meta-analysis indicating that the prevalence of METH-
induced psychotic disorder was 36.5% (37) and these rates
were higher for lifetime prevalence (42.7%) and for those with
METH use disorder (43.3%). In an Australian study of non-
treatment seeking METH users, 13% of the sample population
were positive for psychosis at the time of assessment (32) while
23% reported ‘clinically significant’ symptoms of psychosis over
the previous year. Another study found that 60% of METH-
dependent individuals sampled in the USA reported at least one
type of psychotic symptom (38). Overall, recreational METH
users are two to three times more likely to experience psychotic
symptoms than the general population (39), with their risk
increasing if they began using METH at a younger age or if
large amounts of METH are administered (40). Regular METH
users, on the other hand, are 11 times more likely to experience
psychosis than the general population (41), with the average
time between first use and onset of psychosis being 1.7 years
(42). Furthermore, users of crystallized METH are more likely to
report psychotic symptoms compared to other forms of METH
(43), suggesting that the type and route of administration may
be important factors in determining the likelihood of psychotic
symptoms.
Users are more susceptible to the psychotic effects of METH
whilst they are using the drug. McKetin et al. (15) found that
chronic METH users were 5 times more likely to experience
psychotic symptoms during periods of METH use than during
periods of abstinence. They also found a dose-response effect
between the frequency of METH use and psychotic symptoms,
with psychosis reaching a peak likelihood of 48% following 16
days or more of chronic use. Importantly, these findings were
still significant after controlling for polydrug use, suggesting that
the psychotic symptoms were attributable to the effects of METH
and not due to the interaction of additional drug consumption.
Overall, these findings suggest that METH use is associated with
a high prevalence of psychotic symptoms, which may present
a significant burden on the healthcare system due to increased
demand for care and management of METH-related psychoses.
Indeed, METH psychosis accounted for 10% of admissions to
psychiatric facilities in Thailand (44), and in Australia, METH
psychosis was responsible for 10.3 hospital admissions per
1,000 (45). More recent data has also suggested an increase
in METH psychosis admissions to hospital emergency rooms
and psychiatric facilities over recent years. For example, the
number of admissions to psychiatric units for METH psychosis
in Queensland has increased significantly from 2012 (25) while in
New South Wales, Australia, the number of hospital admissions
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for METH psychosis declined in the mid-2000s but have steadily
increased again since 2010 (46). These findings also appear to be
independent of geographical location, with increased emergency
department admissions for METH psychosis reported in the
Americas (47) and the middle east (48).
CHRONIC METHAMPHETAMINE
PSYCHOSIS
METH psychosis typically follows a transient course, with
symptoms subsiding once the user has stopped taking the drug
(3). Some consumers, however, can experience a prolonged
psychosis that persists even after the drug has cleared from
the body, with the majority of psychotic symptoms resolving
within 1 month (34, 49). Some research has further indicated
that METH psychosis can develop into an enduring form of
psychosis. Reports have suggested that up to 30% of those with
METH psychosis may have symptoms that continue up to 6
months following abstinence (49), with specific studies reporting
15–28% of patients admitted to hospital with METH psychosis
needing hospitalization for more than 2–3 months following
admission (50, 51). Additionally, others have reported that 10–
28% of patients with METH psychosis continued to display
psychosis for more than 6 months (35, 50), while in another
study, 28% of METH-users continued to display “schizophrenia-
like symptoms” 8–12 years following abstinence (52). Outside of
Japan, McKetin et al. (15) reported that even abstinent METH
users had a 7% risk of experiencing psychotic symptoms and
another group found that 5% of abstinent METH-dependent
users met criteria for a psychotic disorder at 3 years follow-up
(53). Furthermore, METH can induce a chronic psychosis in
those with no premorbid psychiatric risk factors (54), suggesting
that METH use can induce persistent physiological changes
consistent with psychosis that are independent to genetic and
personality predispositions. It is recommended that readers
examine many of the comprehensive review articles available
for further information on the clinical profiles, correlates, and
recovery of METH-induced psychosis (55–60). Overall, METH
psychosis can result in a persistent psychotic syndrome that is
resistant to spontaneous recovery, and in light of the high use of
METH use globally, chronic METH psychosis will undoubtedly
continue to be an issue for health-care professionals. As such,
understanding the factors that subserve the neurobiology and
maintenance of chronic psychosis induced by METH abuse will
be important for delineating diagnostic markers and avenues for
treatment.
SCHIZOPHRENIA
Schizophrenia is a severe, complex and debilitating
neuropsychiatric disorder that is traditionally associated with
poor treatment outcomes relative to other psychiatric disorders.
It is a significantly heterogeneous disorder, with symptoms
so diverse and idiosyncratic from patient to patient that the
clinical profile has to be “clustered” into different domains.
While there is no symptom that is sufficient for a person to be
diagnosed with schizophrenia, there are particular symptoms
that aid in differential diagnosis. “Positive symptoms” refer to
symptoms that are usually not present but are experienced by
those with schizophrenia, and include distortions in perceptions
(hallucinations), false beliefs or distorted thought content
(delusions), unclear or confused thinking (thought disorder),
and disorganized speech. These symptoms are generally
interpreted as a loss of touch with reality and are present at
discrete times during “psychotic episodes,” which are considered
a core feature of the disorder (61).While these symptoms can also
be present during remission, medication serves to suppress the
severity and chronicity of these symptoms. “Negative symptoms,”
on the other hand, refer to symptoms or experiences that are
usually absent or diminished in individuals with schizophrenia.
These include social withdrawal, anhedonia, flattened affect,
motor retardation, and poverty of speech (62, 63). Negative
symptoms have a significant bearing on functional engagement
and independence, with negative symptoms shown to predict the
status of future functioning, employment, independence, and
social contact (64).
While both positive and negative symptoms are established
as core symptom dimensions and criteria for schizophrenia
diagnosis in the DSM-5 (65), a third core domain reported is
cognitive dysfunction. A wide range of cognitive domains appear
to be compromised in schizophrenia, with many reviews and
meta-analyses concluding moderate to severe deficits in general
intelligence, attention, working memory, verbal learning and
memory, speed of information processing, visuospatial deficits,
and executive dysfunction (66–71). The cognitive deficits in
schizophrenia are stable across the course of the disorder (72–
75) and are consistent between those with first episode psychosis
and chronic schizophrenia (76–78). However, there is some
evidence that those with earlier onset schizophrenia may have
a decline in cognitive function throughout the progression of
the illness (79). Furthermore, antipsychotic medication appears
to have minimal positive impact, if at all, on the cognitive
difficulties associated with schizophrenia (80). Executive function
appears to be the most compromised and conserved cognitive
deficit across patients with schizophrenia (81, 82), with executive
deficits shown to be the most pervasive amongst older adults
with schizophrenia (83) and negatively impacted by number of
psychotic episodes (84). Additionally, the fact that the cognitive
issues in schizophrenia are deleterious to social functioning,
functional outcomes (85, 86), independence (87, 88), recovery
(89), and well-being (90) has prompted the argument that
cognitive dysfunction should be regarded as one of the core





While a subset of METH users can experience an enduring
form of psychosis, there is uncertainty of the diagnostic
status of chronic METH psychosis as a primary psychotic
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disorder. That is, METH-induced and other substance-induced
psychoses are clearly distinguished from schizophrenia and other
primary psychoses in the Diagnostic and Statistical Manual. In
fact, any psychosis during the withdrawal from a substance
requires the diagnosis of “substance-induced psychotic disorder”
according to the Diagnostic and Statistical Manual (65) and
the International Classification of Diseases, Tenth Revision
(ICD-10). Diagnostic guidelines, however, become ambiguous
should the psychosis persist for an extended period of time.
The DSM-5 outlines that any psychosis that persist longer
than 6 months should warrant the diagnosis of a primary
psychotic illness (65). Indeed, a Thai study of METH abusers,
who were initially hospitalized for METH psychosis found that
38.8% had been diagnosed with schizophrenia due to persistent
psychosis at 5 years follow up (91), and 5.0% of Chinese
patients with METH-induced psychosis had their diagnosis
changed to schizophrenia (49). Longitudinal analyses have
also found that 19.1% (92) to 30% (93) of patients initially
admitted for amphetamine-induced psychosis had transitioned
to a schizophrenia diagnosis at follow-up. Furthermore, a
large study conducted over a 10 year period in the USA
determined that individuals who were hospitalized for METH-
related causes had a higher risk of receiving a subsequent
schizophrenia diagnosis (94). Therefore, while the potential for
METH to induce an acute psychosis is well recognized, the
development of an enduring-form of psychotic disorder, and
its potential to transition into a primary psychotic disorder,
such as schizophrenia, is not as well understood. As these
studies propose that stimulant-induced psychoses represents
a significant precursor to the development of more enduring
forms of psychotic disorders, these findings should guide the
management, early intervention and policy related to METH-
related psychoses to circumvent the progression of these
conditions.
While the above findings support that METH use is
associated with an enduring psychosis, there are several
interpretations of the link betweenMETHuse and schizophrenia.
Firstly, METH could induce schizophrenia by eliciting an
underlying vulnerability/predisposition to a primary psychotic
disorder. Early research on amphetamine psychosis attributed
the continuation of psychotic symptoms to “latent paranoia”
(95). Additionally, a growing body of literature has examined
the role of genetic and environmental interactions in the
development of METH psychosis, with some studies showing
convergence of genetic risk factors for METH psychosis with
those for schizophrenia (58, 96). Additionally, one study found
a significant enrichment of singe nucleotide polymorphisms
(SNPs) for METH psychosis risk in patients with schizophrenia
(97) while another found that a family history of schizophrenia
was a risk factor for the development of METH psychosis
(40, 42, 98). These findings suggest that the development of a
persistent psychotic syndrome, such as schizophrenia, may be
the complex interaction between a predetermined vulnerability
and/or the direct effects of METH as an environmental
trigger (i.e., the two hit hypothesis), and may provide an
explanation as to why only a small percentage of those with
METH psychosis go on to develop a persistent psychotic
syndrome. More recently, however, there has been discussion
surrounding the possibility that METH use could actually
cause the onset of schizophrenia (54, 94, 99), potentially by
inducing schizophrenia pathology. Even though this does not
explain why only a percentage of users develop a persistent
psychotic syndrome, both explanations suggest that METH
psychosis and schizophrenia may be the same disorder on
a continuum of pathology, converging with the idea that
schizophrenia is a neurobiological disorder with multiple
etiologies.
Alternative explanations for METH-induced psychosis may
be possible. As such, it could be that METH psychosis
and schizophrenia represent distinct disorders, and indeed,
several researchers have proposed that METH use in isolation
can produce a persistent psychotic syndrome that should be
diagnosed and treated as a distinct syndrome to schizophrenia
(100, 101). Therefore, given that any persistent psychosis
beyond a 6-month period should be considered as a primary
psychotic disorder, based on the current diagnostic criteria in
the DSM-5, METH psychosis may be routinely misdiagnosed
and treated as schizophrenia. Therefore, the diagnosis of
schizophrenia secondary to METH use described in the
aforementioned studies may merely reflect adherence to
diagnostic protocol and may not be a true reflection of the
status and prevalence of chronic METH psychosis in the
general population. That is, individuals who present with METH
psychosis may be diagnosed with schizophrenia, which may
therefore underestimate the degree to which METH use results
in a persistent psychotic disorder in epidemiological research
studies.
Overall, there appears to be uncertainty about whether
METH use causes schizophrenia or whether chronic METH
psychosis represents a symptomatically distinct disorder that
should be distinguished from other primary psychoses. While
there appears to be similarity between the two conditions,
there is limited research that has explicitly compared the
behavioral and cognitive markers between the disorders. To
understand the similarities and distinguishing features of METH
psychosis and schizophrenia is of benefit. Not only will this
assist in determining the diagnostic entity of METH psychosis,
but will also help develop differential diagnostic markers
for clinicians, better treatment options for long-term METH
psychosis suffers, and will help to delineate common biological
markers across syndromes that may initiate and maintain a
persistent vulnerability to psychosis. This will enable a deeper
theoretical understanding of the specific biological factors that




The current review will describe and critique the literature
that has compared the clinical profile of schizophrenia with (i)
acute METH psychosis and (ii) chronic METH psychosis, with
particular focus on positive, negative and cognitive symptoms.
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While several reviews have examined the clinical profiles, risk
factors, and correlates of METH-psychosis (55, 59, 60) and
cognitive deficits associated with METH use (102–104), the aim
of this study was to provide a comprehensive overview of research
that has directly compared METH psychosis (acute and chronic)
with schizophrenia. Furthermore, while (55) have reviewed
the relationship between METH psychosis and schizophrenia,
we wished to extend this review by differentiating between
acute and persistent forms of METH psychosis. If the use
of METH does cause a primary psychotic disorder, then the
presentation and symptoms of chronic METH psychosis should
match those typically reported in schizophrenia. Consequently,
persistent METH psychosis could be regarded as the same
diagnostic entity and could allude to similar neurobiology and
etiological mechanisms. However, if METH psychosis represents
a biologically and clinically distinct disorder there should be
divergence in the behavioral, cognitive and biological markers
between METH psychosis and schizophrenia.
Inclusion Criteria
Prior to conducting the literature search, inclusion criteria were
formulated from the aims, not only to determine which studies
would be suitable but to provide a unique perspective to the
review and to also minimize the occurrence of methodological
flaws. These included: (1) studies had to based on people,
aged 16 years and older; (2) the current review focused
specifically on research relating to methamphetamine (rather
than amphetamine or other psychostimulants); (3) studies had
examined profiles associated with METH psychosis (i.e., no
studies looking at the cognitive effects of METH without
psychosis); (3) studies had to have directly compared METH
psychosis with schizophrenia or primary psychotic disorder (4)
METH usage had to precede the presentation of psychosis in
order to focus on METH-induced psychotic syndromes; (5)
only original research studies were included (i.e., reviews were
omitted); (6) Case studies were omitted [for a review and
examination of historical case studies of METH psychosis, please
see (59)].
Search Approach
To identify potential studies for inclusion in this review,
the computerized databases of PubMed, PsychINFO and
ScienceDirect were searched. Additionally, reference lists from
retrieved articles were screened to identify omitted articles
from the database search. Lastly, a Google Scholar search
was conducted to ensure that no main article escaped
detection in the literature search. The following search terms
were used to identify potential articles: (methamphetamine
psychosis OR methamphetamine-induced psychosis) AND
(schizophrenia OR primary psychotic disorder) AND (negative
symptoms OR positive symptoms OR psychiatric symptoms OR
cognition).
POSITIVE SYMPTOMS
An overview of the design and findings of individual research
studies that have directly compared METH psychosis with
schizophrenia can be found in Table 1. The methodological
considerations of this research are detailed in Table 2.
Acute Meth Psychosis vs. Schizophrenia
Early findings on METH induced psychosis reported
hallucinations and delusions as a predominant presenting
factor (34, 118), with later findings acknowledging that the
similarities between METH psychosis and schizophrenia
were largely directed toward positive symptoms. McKetin
et al. (32) found that unusual thoughts, hallucinations
and suspiciousness were present in one-quarter of chronic
consumers of METH diagnosed with acute METH psychosis.
Indeed, Bousman et al. (119) examined the variation
in positive symptoms across individuals with METH
psychosis. While they found three distinct sub-profiles,
delusions were common amongst all individuals with
METH-induced psychosis. Additional studies have also
reported that METH psychosis is associated with a high
prevalence of persecutory delusions, auditory and visual
hallucinations, odd speech, and delusions of reference
(15, 40, 60, 113, 119–122).
Of studies that have directly compared acute METH
psychosis with schizophrenia (Table 1), researchers have found
no difference in the type and severity of positive symptoms
using the Positive and Negative Syndrome Scale (PANSS)
(110, 117) or the Brief Psychiatric Rating Scale (BPRS) (111).
There is also research demonstrating that the longitudinal
changes of positive symptoms between METH psychosis and
schizophrenia are similar. For example, Hajebi et al. (117)
conducted a prospective study on individuals with METH-
induced psychosis and found that there was no significant
difference in the severity of positive symptoms (using the
PANSS) between acute METH psychosis and non-affective
psychosis (e.g., schizophrenia) groups on admission, at discharge,
and at 6 and 12-month follow-up. These findings suggest
that the progression of positive symptoms following METH
psychosis is comparable to that of schizophrenia. However,
given that those with METH-induced psychosis continued to
experience symptoms of psychosis following discharge, it is
uncertain whether this group represents acute or chronic METH
psychosis. Furthermore, it should be considered that the non-
affective psychosis group was a heterogeneous sample, consisting
of participants diagnosed with schizophrenia, schizoaffective
disorder and brief psychotic disorder. Collectively, these findings
suggest that the positive symptoms of acute METH-induced
psychosis are qualitatively and quantitatively comparable to the
positive symptoms of schizophrenia, with the initial presentation
of acute METH psychosis indistinguishable from schizophrenia-
related psychosis (113).
Despite the considerable overlap in positive symptoms
between acute METH psychosis and schizophrenia, there
are several differences across both conditions. For example,
Srisurapanont et al. (113) found that while there were no
difference in the type and severity of positive symptoms between
METH psychosis and schizophrenia, the METH psychosis
group tended to have more severe hallucinations and delusions
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compared to schizophrenia. Further analysis revealed that
incoherent speech, a distinguishing marker of thought disorder,
was the only symptom to be differentially expressed between
schizophrenia and METH psychosis. Thought disorder refers to
disorganized thinking and is characterized by the loosening of
associations and fragmented speech (123), and is suggested to
be a defining and salient feature in schizophrenia (124–127).
Although related to amphetamine, initial work by Bell (125)
distinguished between schizophrenia and amphetamine-induced
psychosis with the appearance of thought disorder, as this
symptom was only seen in schizophrenic cases. Additionally, Yui
et al. (127) found that while individuals with METH psychosis
experienced paranoid hallucinations and delusions, the same
participants did not exhibit thought disorder or disorganized
speech. Therefore, the absence of thought disorder may be a
discriminating feature associated with METH psychosis that
can be used to differentiate this disorder from schizophrenia.
However, the use of this potential discriminating feature this
is currently based on indirect and inconclusive evidence, and
further research is needed to determine the differentiation of
thought disorder between METH psychoses and schizophrenia.
Studies that have also differentiated the types of hallucinations
and delusions commonly experienced in METH psychosis and
schizophrenia. Shelly et al. (112), in their examination of first-
rank positive symptoms, found that acute METH psychosis and
schizophrenia demonstrated comparable positive symptoms but
those with acute METH psychosis showed higher frequency of
auditory hallucinations (48.5%) in comparison to schizophrenia
(20.3%). Conversely, thought broadcasting was more prevalent
in the schizophrenia (42%) group compared to METH psychosis
(24%), although this was only significant once age was controlled
for in their analyses. Regardless, these findings are strengthened
by the exclusion criteria of polydrug use for the METH psychosis
group and METH use for the schizophrenia group. Also,
the individuals in the METH psychosis group were deemed
eligible if they were abstinent for no greater than 4 weeks,
highlighting that this represented a true acute psychosis sample.
There is also some evidence that persecutory delusions and
tactile hallucinations may be specific to acute/transient METH
psychosis as opposed to the chronic psychosis and schizophrenia
(109), and indirect comparisons suggest that visual and tactile
hallucinations appear to be more prominent in METH psychosis
compared with schizophrenia (4, 125). Chen et al. (40) reported
that 46.5 and 21.3% of their METH psychosis sample reported
visual and tactile hallucinations, respectively. Additional findings
have also confirmed visual hallucinations in 68.8% of METH
abstinent individuals (128) while others have reported that visual
hallucinations are the fourth most reported positive symptom
in METH psychosis (120). However, visual hallucinations are
typically only reported in severe cases in schizophrenia (129),
with the prevalence rate ranging from 16 to 27% (129,
130). Additionally, formication, a tactile hallucination where
individuals believe that one’s skin has been infested by bugs,
is typically only reported in METH psychosis (131). Therefore,
while auditory hallucinations appear to be the most common
hallucination of both METH psychosis and schizophrenia, visual
and tactile hallucinations appear to be more prominent inMETH
psychosis. However, these later findings are based on indirect
comparisons and not on reliable evidence that has directly
compared METH psychosis with schizophrenia.
Chronic Meth Psychosis vs. Schizophrenia
Researchers have also examined chronic METH psychosis in
relation to schizophrenia. In a small study of 11 patients with
chronic METH psychosis who had been abstinent from METH
for more than 1 month (114) qualitatively reported that five
subjects experienced visual hallucinations, seven experienced
delusions of reference and persecutory delusions while all
experienced auditory hallucinations. Additionally, Yamamuro
et al. (116) found similar PANSS results in their experimental
study examining oxygenation changes in the prefrontal cortex
in acute METH psychosis and schizophrenia during a verbal
fluency task. Furthermore, Wang et al. (115) examined the
positive symptom profile of 52 individuals with chronic METH
psychosis (who experienced psychosis and had been abstinent
from METH for more than 1 month) and compared this to
53 participants with schizophrenia. They found no difference
in the patterns of delusions experienced between those with
chronic METH psychosis and schizophrenia and that auditory
hallucinations were the most common type of hallucination
experienced between groups. However, those with chronic
METH psychosis significantly experienced greater visual and
tactile hallucinations relative to schizophrenia while those with
schizophrenia endorsed greater conceptual disorganization. This
suggests that thought disorder may be specific to schizophrenia
and not present in either acute or chronic METH psychoses
while tactile/visual hallucinations, such as formication, may be
more reflective of METH-induced psychoses. These findings are
strengthened by the fact that those in the METH psychosis group
could only be included if their psychosis occurred after the use
of METH, and those in the schizophrenia group could not have a
history of drug use disorder, meaning that the diagnosis of each
psychiatric condition was independent to the effect of several
confounds.
The profiles of acute METH psychosis, persistent METH
psychosis and schizophrenia have also been compared. Chen
et al. (105) examined the positive symptoms experienced by
those with acute METH psychosis (experienced psychosis for
<1 month following abstinence), persistent METH psychosis
(psychosis presents following abstinence from METH > 1
month) and schizophrenia using the PANNS. Those with
persistent METH psychosis and schizophrenia demonstrated
comparable severity and frequency of positive symptoms, and
both of these groups had PANNS scores that were significantly
higher than those in the acute METH psychosis group. These
findings may suggest that those with acute METH psychosis
may not experience positive symptoms to the same frequency
and severity as those with schizophrenia and chronic METH
psychosis. However, it should be noted that those in the acute
METH group were abstinent for an average of 9 weeks at the
time of assessment, and therefore, the results may not truly reflect
the severity of these symptoms experienced at the time of their
psychotic episodes.
Frontiers in Psychiatry | www.frontiersin.org 13 October 2018 | Volume 9 | Article 491
Wearne and Cornish Methamphetamine Psychosis With Schizophrenia Comparison
Recently, McKetin et al. (109) classified 284METH dependent
participants as experiencing no current psychotic symptoms,
transient psychotic symptoms when using METH, psychotic
symptoms during METH use and more than 1 month abstinent
(i.e., persistent METH psychosis) or as experiencing primary
psychosis (i.e., schizophrenia), and examined the lifetime
experience of hallucinations and delusions between groups.
Relative to acute METH psychosis, it was shown that persistent
METH-induced psychosis was associated with greater lifetime
experiences of thought interference and delusions of reference
while primary psychosis was likely to experience the same
symptoms in addition to thought projection, erotomania,
olfactory hallucinations and passivity (relative to acute METH
psychosis). Furthermore, those with persistent METH psychosis
and schizophrenia also reported reduced symptoms of visual
and tactile hallucinations relative to those in the transient
METH psychosis group. Importantly, the lifetime delusion and
hallucination symptom profiles were not significantly different
between persistent METH psychosis and primary psychosis,
suggesting that the positive symptoms are comparable between
the two conditions. However, it should be noted that those
in the primary psychosis group were also METH dependent,
suggesting that the results are not independent to drug effects,
and as the authors indicate, those in the primary psychosis
group may have experienced mania as opposed to schizophrenia.
Furthermore, the authors examined the lifetime prevalence
of psychotic symptoms, rather than those experienced during
their psychotic episodes, which may explain why there was no
differences between chronic psychotic syndromes. Nevertheless,
these findings suggest that patients who present with greater
severity and frequency of lifetime delusions and hallucinations
(particularly thought interference, delusions of references and
auditory hallucinations) may be at increased risk for the
development of recurrent psychotic episodes or a primary
psychotic disorder.
NEGATIVE SYMPTOMS
An overview of the design and findings of individual research
studies that have directly compared negative symptoms in those
with METH psychoses to those with schizophrenia can be
found in Table 1. The methodological considerations in the
examination of research that has compared symptoms between
METH psychosis and schizophrenia is shown in Table 2.
Acute Meth Psychosis vs. Schizophrenia
While stimulant-induced psychotic disorders have been
predominantly characterized by positive symptoms, negative
symptoms such as flat affect, social withdrawal, apathy, loss of
drive, anhedonia and poverty of speech have also been reported
in METH psychosis samples (4, 40, 113, 123, 132). Srisurapanont
et al. (113) showed no difference between METH psychosis
and schizophrenia on measures of psychomotor retardation,
flattened affect and poverty of speech using the Manchester scale,
while other researchers have found no significant differences
between METH psychosis and schizophrenia using the BPRS
(107) or the PANSS (111).
However, some researchers have shown differences in the
severity of negative symptoms experienced between acute
METH psychosis and schizophrenia. For example, Hajebi et al.
(117) found that on admission to hospital, those with non-
affective psychosis had more severe negative symptoms than
those with acute METH-psychosis. Furthermore, while the
severity of negative symptoms had improved for both groups
upon discharge, the non-affective psychosis group continued
to maintain increased severity of negative symptoms relative
to the acute METH-psychosis group. There is also indirect
evidence that negative symptoms are less severe in acute METH
psychosis compared to schizophrenia. Negative symptoms are
common in schizophrenia, with negative symptoms considered
a central feature of its phenomenology and diagnostic criteria
(133, 134). Indeed, 58% of individuals with schizophrenia
experience negative symptoms (135), with 50–90% of those
with schizophrenia displaying negative symptoms in first-episode
psychosis (136). On the other hand (132) found that only 25% of
individuals hospitalized withMETHpsychosis exhibited negative
symptoms while (122) similarly found that only 21.4% of their
sample met criteria for negative symptoms in a clinical interview
using the MINI-plus. While these lower prevalence rates may
be attributable to limited research in the area, specifically with
respect to inclusion and appropriate assessment of negative
symptoms in research studies, these findings suggest that negative
symptoms may be experienced at a considerably lower rate in
acute METH psychosis compared with schizophrenia.
Chronic Meth Psychosis vs. Schizophrenia
Previous research has explicitly compared the negative symptoms
between chronicMETH psychosis and schizophrenia. Tomiyama
(114) examined the experience of negative symptoms between 11
participants with chronic METH psychosis and 11 participants
with schizophrenia using the Scale for the Assessment of Negative
Symptoms (SANS). They found that negative symptoms were
milder in chronic METH psychosis overall when compared
to schizophrenia. When examining the individual symptoms,
however, they found that ratings of avolition-apathy, anhedonia-
asociality, and attentional impairment were similar between both
groups, but those with schizophrenia demonstrated elevated
symptoms of affective flattening and alogia. Additionally, Wang
et al. (115) found that schizophrenia was associated with greater
frequency and severity of negative symptoms compared to
those with chronic METH psychosis. Specifically, those with
schizophrenia demonstrated elevated scores for blunted affect,
emotional withdrawal and motor retardation. Furthermore, in
differentiating between acute and chronic METH psychosis with
schizophrenia (105), using the BPRS, found that those with
schizophrenia demonstrated the greatest severity of negative
symptoms compared to those with acute and chronic METH
psychosis, but the negative symptoms demonstrated by the
chronic METH psychosis group were significantly greater than
those in the acute METH group. Therefore, even though negative
symptoms have been reported in both schizophrenia and METH
psychosis, schizophrenia appears to be associated with greater
prevalence and severity of negative symptoms compared to
METH psychoses.
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COGNITIVE SYMPTOMS
An overview of the design and findings of individual research
studies that have directly compared the cognitive symptoms
associated with METH psychosis to those of schizophrenia can
be found in Table 1. The methodological considerations in the
examination of research that has compared symptoms between
METH psychosis and schizophrenia is shown in Table 2.
Acute Meth Psychosis vs. Schizophrenia
Recent work has examined the prevalence and severity of
cognitive dysfunction following acute METH psychosis in
comparison with schizophrenia. Jacobs et al. (108) in an
exploratory cross-sectional study, compared the cognitive profile
of individuals hospitalized with METH psychosis with patients
with paranoid schizophrenia across eight cognitive domains,
including premorbid intellectual ability, learning and memory,
executive functioning, general intellectual functioning, attention
and concentration, motor abilities together with non-verbal and
verbal skills. They found no significant differences between
the two groups in any cognitive domain examined, suggesting
that both METH psychosis and schizophrenia may have similar
cognitive profiles and may therefore share underlying brain
pathology, particularly with respect to dysfunction of the frontal
and temporal lobes. However, there are several limitations
to these findings. Firstly, the groups had small sample sizes.
Secondly, there were between-group differences in age, ethnicity
and place of birth between those with METH psychosis
and schizophrenia and as such, these factors may have been
confounds in the study. Additionally, it was not known how
long the sample had been abstinent from METH nor was it
reported how long the METH psychosis sample had been taking
METH prior to their participation in the study. Regardless, this
initial study suggested that METH psychosis may show cognitive
deficits, similar to those typically reported in schizophrenia.
Ezzatpanah et al. (106) further compared cognitive function
in individuals with METH-induced psychosis and schizophrenia
to healthy controls, with all subjects matched for age, sex
and education. They found that both METH psychosis and
schizophrenia were characterized by reduced performance on all
cognitive tasks examined when compared to healthy controls,
and there were no significant differences in the performance of
those with acute METH psychosis and schizophrenia across tasks
of memory, sustained attention, selective attention and executive
functioning. Specifically, METH psychosis and schizophrenia
groups demonstrated difficulty in inhibiting, manipulating and
suppressing information, together with difficulties learning
and retaining verbal information over time. These findings
indicate that both disorders may be characterized by comparable
deficits of cognition mediated by the temporal and frontal
lobes, specifically the prefrontal cortex, and further extends the
findings of Jacobs et al. (108) that both METH psychosis and
schizophrenia may be the product of similar pattern of brain
pathology. While both these studies were hampered by small
sample sizes, these similar findings are strengthened by the
fact that these two studies were derived from different cultural
samples - American (108) and Iranian (106)–and through
the use of distinct cognitive measures. However, despite the
overwhelming similarities in cognitive dysfunction between
METH psychosis and schizophrenia (106) found that individuals
with schizophrenia and METH psychosis demonstrated
difficulties with sustained visual attention compared to controls,
yet those with schizophrenia performed worse than subjects with
acute METH psychosis. As selective visual attention is primarily
correlated with the parietal cortex (137), these findings indicate
that dysfunction of the parietal cortex may be more pronounced
in schizophrenia than acute METH psychosis.
Chronic Meth Psychosis vs. Schizophrenia
The above studies were based on recent abstinent METH users
and may not be generalizable to those with chronic METH
psychosis. However, there is emerging evidence of similarities
between cognitive symptoms in persistent METH psychosis and
schizophrenia in the literature. For example, (116) examined
individuals with METH psychosis and schizophrenia on a verbal
fluency tasks while they had their brain blood oxygenation levels
recorded using Functional Near-Infrared Spectroscopy (NIRS).
They also had their cognitive ability measured using the Brief
Assessment of Cognition in Schizophrenia (BASC). They found
there was no difference between those with METH-psychosis
and schizophrenia on tasks of verbal memory, working memory,
motor speed, verbal fluency, attention, speed of information
processing, executive functioning and total cognitive ability.
However, oxyhaemaoglobin changes in the prefrontal cortex were
higher in theMETH psychosis group compared to schizophrenia,
particularly in the right dorsolateral prefrontal cortex. This
suggests that while the cognitive ability may be similarly
perturbed across METH psychosis and schizophrenia, there are
biological changes that may be used to distinguish between the
two conditions. However, a significant limitation in this study
is that the length of abstinence for the METH psychosis group
was not stated. Given that the sample had been 8.42 years since
the onset of psychotic symptoms (average of 2.5 hospitalizations
and 8.42 months of hospitalization), the sample likely reflects a
more persistent METH psychosis, and the researchers referred to
the sample as “methamphetamine-induced psychotic disorder.”
However, in the absence of abstinence information, it is uncertain
whether these findings are applicable to acute or chronic METH
psychosis, or the sample could reflect a blended representation.
More recent research has shown that cognitive dysfunction
is specific to the persistent form of METH psychosis rather
than acute METH psychosis. For example, Chen et al. (105)
conducted a well-designed cross-sectional study on healthy
controls, METH users without psychosis, METH users with
acute psychosis (METH users who had psychotic symptoms
that dissipated within 1 month following abstinence), METH
users with persistent psychosis (psychosis greater than 1 month),
and individuals with schizophrenia. They found that METH
users with persistent psychosis performed comparably to those
with schizophrenia across all cognitive domains, with both these
groups performing worse than the other acute METH psychosis,
METH users without psychosis and control groups. These
findings extend the findings of Jacobs et al. (108) and Ezzatpanah
et al. (106) by clearly distinguishing between METH users with
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acute and persistent psychoses, suggesting that schizophrenia and
only persistent psychosis secondary to METH use are associated
with similar cognitive profiles. This may indicate that the samples
used in previous studies could represent a mixture of both
acute and persistent METH psychoses. These findings therefore
suggest that cognitive dysfunction may develop in individuals
who originally had acute symptoms that endured over time,
likely as a secondary consequence to neuropathological changes
that coincide with abstinence. Altogether, these findings indicate
that chronic METH-induced psychosis is associated with brain
changes that may be carefully distinguished from the changes
concomitant with METH use and acute METH psychosis.
METHODOLOGICAL LIMITATIONS AND
CONSIDERATIONS
An overview of the methodological considerations in the
examination of research that has compared symptoms between
METH psychosis and schizophrenia is shown in Table 2. One
of the biggest limitations with METH psychosis research is that
little effort is made to distinguish between those with acute
and chronic METH psychosis, with the majority of the findings
portraying a blended representation of all types. Indeed, the
majority of studies failed to report the length of time of abstinence
fromMETH at the time of the assessment. For the purpose of this
review, therefore, we considered these studies to represent acute
METH psychosis studies as there was no evidence to suggest
that these samples had been abstinent for long enough to be
considered to be representative of chronic METH psychosis [>1
month abstinence according to published papers, e.g., (105)].
Additionally, few studies indicate whether their samples are
abstinent at the time of the assessment. Taken together, the
findings presented in these papers may not be generalizable to
samples of chronic METH psychosis, as it is uncertain whether
these behavioral outcomes are referable to the direct effects of
METH, acute METH psychosis or persistent METH psychosis.
In keeping with this limitation, some studies implement
diagnostic criteria for chronic METH psychosis that is distinct
by those provided by the DSM-5. That is, these studies
typically categorize those who continue to experience psychosis
after discontinuing METH for more than 1 month as those
with persistent METH psychosis. According to the DSM,
however, these patients should be diagnosed with a primary
psychotic disorder, and some studies adhere to these guidelines.
Consequently, individuals with chronic METH psychosis may be
categorized as participants with schizophrenia. There are several
implications to this procedure. Firstly, chronic METH psychosis
may be underreported across scientific literature. Secondly, the
inappropriate allocation of participants to treatment conditions
precludes the examination of distinct clinical and symptom
profiles between conditions given the significant heterogeneity
across various outcome measures. Furthermore, inconsistency
in sample characteristics hinders the ability to pool data and
conclusions across research studies. Indeed, it is worth noting
that other researchers have proposed similar concerns about this
approach to METH psychosis research (138). Given that only
METH users with a persistentMETH psychosis syndrome appear
to display the cognitive dysfunction typically associated with
schizophrenia (105), it is possible that the differences in positive,
negative and cognitive symptoms reported in additional studies
may refer only to acute METH psychosis. It will be important
for future research to examine the effect of persistent METH
psychosis and how this relates to the behavioral, cognitive and
biological changes typically reported in schizophrenia in order to
elucidate whether chronic METH psychosis represents a distinct
psychotic disorder and to differentiate the clinical profiles of
acute vs. chronic psychosis forms.
There are additional limitations to this field of research
that should be addressed. Firstly, many studies are of low
sample size, meaning that many of the similarities between
METH psychosis and schizophrenia may be due to low
statistical power to detect significant difference between groups.
Secondly, many studies do not control for polydrug use,
meaning that the symptoms of psychosis may not be exclusively
attributed to METH administration. Thirdly, studies do not
actively control for the effect of psychotropic medication,
particularly given that this impacts on the presentation of
behavioral symptoms. Additionally, many studies are reliant
on hospitalized samples, which are likely concomitant with
more severe psychosis than non-treatment-seeking individuals
with METH psychosis in the community. Lastly, many studies
compare METH psychosis to schizophrenia using screening
or brief assessment tools. A significant limitation of these
scales is that they do not differentiate the qualitative nature of
the hallucinations or delusions experienced, as they quantify
the status of positive symptoms with a total score, meaning
that these scales may be unable to detect differences that
may differentiate these conditions. The use of such tools may
explain why research studies produce such contrasting, and
at times conflicting, clinical profiles. For example, the positive
symptoms associated with METH psychosis and schizophrenia
using the PANSS and BPRS are comparable, but examination
using more indepth tools, such as the Manchester Scale, revealed
differences in the type of positive symptoms experienced between
groups.
SUMMARY AND CONCLUSIONS
A comparison of the positive, negative and cognitive symptoms
between schizophrenia and acute/chronic METH psychosis is
detailed in Figure 1. Research has shown both similarities and
differences in the positive, negative and cognitive symptoms
between METH-induced psychosis and schizophrenia. There
appears to be a high degree of concordance in the type,
prevalence and severity of positive symptoms between METH-
induced psychosis and schizophrenia, confirming that it would
be difficult to distinguish between the two conditions in
the clinical setting based on the positive symptoms alone.
However, while auditory hallucinations appear to be the
most common hallucination reported in METH psychosis
(acute and chronic) and schizophrenia, visual and tactile
hallucinations appear to be more prominent in acute/transient
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FIGURE 1 | Venn diagram of the overlap in psychiatric and cognitive symptomatology between acute METH psychosis, chronic METH psychosis, and schizophrenia.
The left represents symptoms specific to acute METH psychosis, the right (highlighted blue) represents the symptoms and profile specific to chronic METH psychosis,
while the bottom highlights those associated specifically with a schizophrenia profile. Symptoms that are common across disorders are shown in the overlap. aAll
conditions demonstrate some degree of positive, negative and cognitive symptomatology according the specific syndrome scales (e.g., Brief Psychiatric Rating Scale
or the Positive and Negative Severity Scale). bVisual and tactile hallucinations: Acute METH psychosis > Chronic METH psychosis > Schizophrenia cSeverity of
negative symptoms: Schizophrenia > Chronic METH psychosis > Acute METH psychosis. dCognition: Schizophrenia = Chronic METH psychosis > Acute METH
psychosis.
METH psychosis, with thought disorder the most pronounced
symptom in schizophrenia. While negative symptoms occur in
both conditions, some research has indicated that there are
differences in the type, severity and progression of negative
symptoms throughout both conditions, with METH psychosis
associated with reduced frequency and severity of several
negative markers, such as flattened affect (although chronic
psychosis is associated with worse negative symptoms than
acute METH psychosis). Lastly, from a cognitive perspective,
most cognitive domains appear to be similarly perturbed
across METH psychosis and schizophrenia. However, recent
findings have highlighted that some functions subserved by
the parietal cortex, such as selective visual attention, may
be more pronounced in schizophrenia that acute METH
psychosis, and that cognitive dysfunction may be specifically
comparable to schizophrenia for those with chronic METH
psychosis.
Overall, while there is considerable overlap in the behavioral
and cognitive symptoms between acute METH psychosis
and schizophrenia, research has shown that there are unique
aspects to each condition. While both disorders may be
characterized by common underlying biological pathologies
and phenotypes, acute METH psychosis could represent a
distinct psychotic disorder to schizophrenia and may be
clinically distinguished from a primary psychotic disorder
based on distinct behavioral and cognitive sequelae. On
the other hand, preliminary evidence suggests that chronic
METH psychosis may be clinically similar to that of primary
psychotic disorders, particularly with respect to positive
and cognitive symptomatology. However, given the number
of limitations evident in the available studies, particularly
with respective to the paucity of experimental designs
that differentiate between acute and chronic forms of
METH psychosis, there is insufficient evidence to conclude
whether chronic METH psychosis is clinically distinct from
schizophrenia.
Nevertheless, these findings may have implications for the
longer-term management and treatment of such conditions.
For example, concerning the management of acute METH
psychosis, symptoms will resolve with abstinence from METH
and with the appropriate management of withdrawal. Therefore,
for the most part, long-term pharmacological interventions
for acute METH psychoses would not be needed or beneficial
(139). However, given the similarity in symptoms between
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persistent METH psychosis and schizophrenia, second
generation antipsychotic medicines, such as risperidone
and olanzapine, may be appropriate intervention strategies.
While first-generation anti-psychotics (i.e., haloperidol) may
useful for the management of schizophrenia, and therefore,
persistent METH psychosis, such medicines are at elevated
risk of causing extrapyramidal symptoms in individuals with
METH induced psychosis, and should therefore be used
carefully (56, 140). However, these suggestions are not clinical
recommendations and should be further examined using
large randomized clinical trials so that clinical guidelines
on the appropriate treatment of these conditions can be
developed.
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